麻豆传媒

Mark is the Queen's Lead of the 拢5M Medical Research Council-Cancer Research UK funded Stratified Medicine in Colorectal Cancer Consortium (S:CORT), a UK-wide consortium investigating novel precision medicine approaches in colorectal cancer(CRC). His international reputation in CRC was instrumental in his leading a Critical Gaps in Colorectal Cancer Research Initiative, recently published in the high impact factor journal Gut; this landmark publication has attracted significant global attention (his podcast had the most 鈥渉its鈥� of any article in the journal)    

Mark is Queen's Lead of the Health Data Research UK Substantive Site, one of only 6 in the UK, which aims to drive innovative precision medicine and public health approaches through the use of Big Data. He is also national lead for Cancer Strategy for HDR-UK. Mark was co-chair of the Cancer Task Team of the Clinical Working Group of the Global Alliance for Genomics and Health (GA4GH), an international cooperative dedicated to effective and responsible sharing of genomic and clinical data. He has authored a number of key papers including a blueprint for cancer date sharing (published in Nature Medicine) and a road map/call to action for a Global Cancer Knowledge Network in the New England Journal of Medicine 

Mark has published over 180 papers in international peer review journals, including key papers in the highest impact journals (New Engl J Medicine, Lancet, Nature Medicine, Lancet Oncology, Cancer Discovery, Nature Comms, Gut etc). He is co-lead of an ambitious proposal to develop a Global Innovation Institute in Belfast which will include the  One Health Innovation Centre (OHIC), the world鈥檚  first Health and Agri-Food Informatics Innovation Centre.  Mark鈥檚 work has been recognised by a number of national/international awards including the Vander Molen Prize for Leukaemia Research, the Ely Lilly Prize, the St Lukes Medal for Cancer Research and the Graves Medal for Medical Research. He is frequently invited as a guest speaker to international conferences and sits on a number of high level boards/committees at European level including the European Alliance for Personalised Medicine, the Scientific Board of the European Cancer Patient Coalition and the European Cancer Organisation (ECCO) Oncopolicy Forum    

Mark has a strong commitment to patient-centred research/care and to addressing cancer inequalities. He was the architect of the European Cancer Patient's Bill of Rights (BoR), a catalyst for change and empowerment tool for cancer patients which he launched in the European Parliament on World Cancer Day 2014. The BoR has been adopted across Europe and led to the 70:35 Vision, 70% survival for all cancer patients in Europe by 2035 which was recently adopted by ECCO, the largest interdisciplinary cancer organisation in Europe. Mark鈥檚 advocacy work was instrumental in the recent decision to include boys in national UK HPV vaccination programmes.  He is also committed to the provision of optimal pathology and laboratory medicine for citizens in resource-limited settings and was senior author of a recent paper in The Lancet as part of The Lancet Series on Pathology and Laboratory Medicine in Low- and Middle- Income Countries. 

Roy A. Jensen, M.D. earned his bachelor鈥檚 degree in Biology and Chemistry from Pittsburg State University in 1980. He graduated from Vanderbilt University School of Medicine in 1984, and remained there to complete a residency in Anatomic Pathology and a Surgical Pathology fellowship under the direction of Dr. David L. Page. Following his clinical training he accepted a biotechnology training fellowship at the National Cancer Institute in the laboratory of Dr. Stuart Aaronson. He returned to Vanderbilt in 1991 and was appointed an assistant professor in the Departments of Pathology and Cell Biology. In 1993 Dr. Jensen was appointed as an investigator in the Vanderbilt-Ingram Cancer Center and assumed the management of the Human Tissue Acquisition and Pathology Shared Resource.  Dr. Jensen was promoted to associate professor of Pathology and Cell Biology in 1996, and was appointed as an associate professor of Cancer Biology in 2001.

In 2004, Dr. Jensen returned home to Kansas and was appointed the William R. Jewell, M.D. Distinguished Kansas Masonic Professor, the director of The University of Kansas Cancer Center, the director of the Kansas Masonic Cancer Research Institute, professor of Pathology and Laboratory Medicine, and professor of Anatomy and Cell Biology at the University of Kansas Medical Center. He also holds appointments as a professor in the Department of Molecular Biosciences at the University of Kansas-Lawrence and as professor in Cancer Biology at The University of Kansas Medical Center. Dr. Jensen is currently serving as president of the Association of American Cancer Institutes (AACI) and is a member of several scientific and professional societies including the American Association for Cancer Research, the American Association for the Advancement of Science, the American Society for Cell Biology, the American Society for Investigative Pathology, and the United States and Canadian Academy of Pathology. He currently has over 150 scientific publications and has lectured widely on the clinical and molecular aspects of breast cancer pathology. Dr. Jensen's research interests are focused on understanding the function of BRCA1 and BRCA2 and their role in breast and ovarian neoplasia; and in the characterization of premalignant breast disease both at the morphologic and molecular levels. His laboratory was instrumental in demonstrating the role of BRCA1 in the growth control of normal and malignant cells and in how loss of functional BRCA1 contributes to the development of breast cancer.

Since becoming director of The University of Kansas Cancer Center in 2004, he has recruited a world-class leadership team and successfully led that team in achieving designation for The University of Kansas Cancer Center as a National Cancer Institute designated cancer center.

In 2009, she joined the Department of Pathology & Molecular Medicine at McMaster University and was promoted to associate professor in 2014. In 2019, she was promoted to tenure professor in the same department. The Bowdish lab focuses primarily on the effects of aging on the immune system, specifically macrophages. Her lab has been able to elucidate a mechanistic explanation for how aging alters myeloid cells and how these cells increase susceptibility to pneumococcal pneumonia. In 2017, the Bowdish lab demonstrated that age-associated gut microbe dysbiosis in mice increases age-associated inflammation. Bowdish currently holds an h-index score of 38. Bowdish's published works have received much media attention and continue to contribute more information regarding the interplay between the immune system, the gut microbiota, susceptibility to infection and aging.

Emily E. Volk, MD, MBA, FCAP is the Senior Vice President, Clinical Services for University Health System in San Antonio, Texas. In addition, as a Clinical Assistant Professor of Pathology at the University of Texas-Health, she practices cytopathology and surgical pathology. Dr. Volk, board-certified in anatomic and clinical pathology with subspecialty certification in cytopathology, received her medical degree from the University of Missouri-Kansas City in 1993. Dr. Volk completed her pathology residency training with a certification year in Surgical Pathology with an emphasis in Gastrointestinal Pathology at the Cleveland Clinic Foundation in Cleveland, Ohio in 1998. Dr. Volk completed her fellowship in cytopathology at William Beaumont Hospital, Royal Oak, MI. Dr. Volk serves on the Executive Board of the Texas Society of Pathologists and is past president of the Michigan Society of Pathologists. At the College of American Pathologists, she serves on the Board of Governors and is the Vice-Chair of the Council and Government Professional Affairs. She chairs the Pathologists Quality Registry Committee for the CAP.

Dr. S. Wesley Long received his MD degree in 2007 from The University of Texas Medical Branch (UTMB) in Galveston TX, where he also earned a PhD in Experimental Pathology. After finishing his doctoral studies, Dr. Long completed a clinical pathology residency at Houston Methodist. He currently serves as a member of the Editorial Board for Archives of Pathology and Laboratory Medicine. Dr. Long’s research centers on functional genomics of multidrug-resistant bacterial strains to identify novel drug targets. He is currently focusing his work on MRSA (methicillin-resistant Staphylococcus aureus) and Klebsiella pneumoniae, both of which readily acquire resistance to several different types of antibiotics and are prevalent in the hospital setting.

Ie-Ming Shih is one of the world鈥檚 leading scientists and pathologists for women鈥檚 cancers. He has led and contributed to a new paradigm in the origin of ovarian cancer, which upends decade鈥檚 old view and posits that ovarian cancers arise from the oviduct rather than from the ovary.  This may explain why current strategies of early detection fail. Shih is leading collaborative research to understand the molecular landscape and evolutionary history of early ovarian cancer, use routine Pap smears to detect oviduct precancer lesions that travel down to the opening of the uterus and advocate to remove fallopian tubes in women for prevention, if there is a surgical opportunity.

Dr. Ranjit Bindra is a physician-scientist at Yale School of Medicine and Co-Director of the Yale Brain Tumor Center at Smilow Cancer Hospital. In the laboratory, his group recently led a team of four major laboratories at Yale, which reported the stunning discovery that IDH1/2-mutant tumors harbor a profound DNA repair defect that renders them exquisitely sensitive to PARP inhibitors. This work was published in Science Translational Medicine, and Nature, and it has received international attention with major clinical implications Dr. Bindra is now translating this work directly into patients, in four phase I/II clinical trials, including an innovative, biomarker-driven trial specifically targeting the Adolescent/Young Adult (AYA) cancer patient population. In addition, he is lead co-PI of a 35-site, NCI-sponsored Phase II trial testing the PARP inhibitor, olaparib, in adult IDH1/2-mutant solid tumors (NCT03212274). As a biotech entrepreneur he recently co-founded Cybrexa Therapeutics, a Series B round-funded company focused on developing an entirely new class of small molecule DNA repair inhibitors, which directly target the tumor microenvironment. Dr. Bindra received his undergraduate degree in Molecular Biophysics and Biochemistry from Yale University in 1998, and both his MD and PhD from the Yale School of Medicine in 2007. He completed his medical internship, radiation oncology residency, and post-doctoral research studies at the Memorial Sloan-Kettering Cancer Center (MSKCC) in 2012.

Education & Training
Resident
Memorial Sloan-Kettering Cancer Center (2012)
Intern
Memorial Sloan-Kettering Cancer Center (2008)
MD
Yale University School of Medicine (2007)
PhD
Yale University Graduate School (2005)
BS
Yale University (1998)

Katerina Politi studied Biology at the University of Pavia in Italy. She then moved to New York, where she obtained her PhD in Genetics and Development working with Argiris Efstratiadis at Columbia University. Following graduate school, she joined Harold Varmus's lab at Memorial Sloan-Kettering Cancer Center and began her work on the molecular basis of lung cancer. She continues this work at Yale as an Associate Professor in the Department of Pathology and the Yale Cancer Center.

David Rimm is the Anthony N. Brady Professor of Pathology in the Departments of Pathology and Medicine (Oncology) at the Yale University School of Medicine. He is the Director of Yale Pathology Tissue Services and the Lab for Quantitative Diagnostics in Anatomic Pathology. He completed an MD-PhD at Johns Hopkins University Medical School followed by a Pathology Residency at Yale and a Cytopathology Fellowship at the Medical College of Virginia. His research lab group focuses on quantitative pathology using the AQUA® technology invented in his lab, and other quantitative methods, with projects related to predicting response and resistance to both targeted and immune- therapy in cancer. His lab is involved in the use of new high-plex methods including digital spatial profiling (NanoString) for new biomarker discovery. He is also interested in translation of assays to the clinic and standardization of those assays for CLIA labs. The work is supported by grants from the NIH, BCRF, and sponsored research agreements from biopharma. He also serves on the CAP Immunohistochemistry committee and multiple scientific advisory boards for biotech and pharma. He is an author of over 500 peer-reviewed papers with an H-index of 120 and 8 patents.

Church is a board-certified Pediatric Pathologist and Molecular Genetic Pathologist. She is the Associate Director of the Laboratory for Molecular Pediatric Pathology (LaMPP) at Boston Children’s Hospital, and an Assistant Professor at Harvard Medical School.? She has participated in several high-impact studies using molecular profiling for pediatric cancers, including the?iCat?study, Profile study, and the ongoing multi-institutional GAIN consortium study and Broad Institute's Count Me In study.? Her career is dedicated to implementing high-quality accessible molecular profiling tests to support the care of children with cancer.

Dr. Rong Fan is the Harold Hodgkinson Professor of Biomedical Engineering and of Pathology. His research interest has been centered on the development and deployment of single-cell and spatial omics technologies to investigate normal development, aging, and disease. He received a B.S. in Applied Chemistry from University of Science and Technology of China, a Ph.D. in Chemistry from the University of California at Berkeley, and then completed his postdoctoral training at California Institute of Technology, prior to joining the faculty of Department of Biomedical Engineering at Yale University in 2010. He developed a microchip that allows for simultaneous measurement of 42 immune effector proteins in single cells at high throughput, which remains the highest multiplexing to date for a single-cell protein secretion assay. In collaboration with Novartis and Kite Pharma, it was applied to profiling antigen-specific activation states of chimeric antigen receptor (CAR)-engineered T cells, resulting in the discovery of novel single-cell biomarkers including polyfunctional strength index to characterize the quality of CAR-T infusion products and predict the clinical responses and immune-related adverse effects(irAEs) prior to treatment. This microchip, called IsoCode, and the automation system, called IsoLight, have been commercialized by IsoPlexis, a company co-founded by Dr. Fan. Now, this system has been used by >100 major pharmaceutical companies and cancer centers around the world for monitoring CAR-T or checkpoint inhibitor immunotherapies. Dr. Fan is also a pioneer in developing NGS-based spatial omics sequencing technologies. He conceived the concept of spatial multi-omics and developed the first spatially resolved multi-omics sequencing technology called DBiT-seq (Liu et al., Cell 183, 1665–1681, 2020) which allows for spatial co-profiling of whole transcriptome and hundreds of proteins (spatial-CITE-seq) at cellular level in complex tissues. He further developed a first-of-its-kind technology to enable spatial epigenome sequencing including spatial-ATAC-seq (Deng et al., Nature 609 (7926), 375-383, 2022) and spatial-CUT&Tag (Deng et al., Science 375 (6581), 681-686, 2022). These technologies may unlock a whole new field in spatial biology with applications in a wide range of biological and biomedical research. Dr. Fan co-founded IsoPlexis, Singleron Biotechnologies, and AtlasXomics. He is the recipient of multiple awards including the NCI Howard Temin Career Transition Award, the NSF CAREER Award, and the Packard Fellowship for Science and Engineering. He has been elected to American Institute for Medical and Biological Engineering (AIMBE), Connecticut Academy of Science and Engineering (CASE), and the National Academy of Inventors (NAI).